Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Dr. Camilla Nord serves as Assistant Professor of Cognitive Neuroscience at the University of Cambridge's Department of Psychiatry and is Programme Leader at the MRC Cognition and Brain Sciences Unit. She holds dual appointments as Co-Director of Postgraduate Education & Director of the MPhil in Cognitive Neuroscience at the MRC CBU, and as Fellow and Director of Studies at Christ's College Cambridge. Nord directs the Mental Health Neuroscience Lab (nordlab.co.uk), which focuses on translating neuroscience into improved mental health treatments through innovative pharmacological, psychological, and neurostimulation interventions. Her research spans three interconnected streams: Discovery Science investigates brain-body interactions including interoception, circadian rhythms, and metabolism as neglected sources of mental health information; Experimental Medicine employs pharmacological manipulation, brain stimulation, and psychological interventions to establish causal relationships between physiological mechanisms and mental health conditions; and Translational Neuroscience develops clinical trials for neuroscience-based interventions, particularly 'acute augmentations' that enhance psychological therapy efficacy. Her lab has demonstrated how gut states cause disgust avoidance and how psychological therapy techniques alter negative learning processes. Analysis of Nord's publication record reveals a strong emphasis on computational approaches to mental health, with particular focus on depression treatment mechanisms. Her work increasingly integrates brain-body interactions, especially gut-brain and metabolic pathways, into mental health frameworks. Recent publications show growing emphasis on patient-centered research, interoception, and transdiagnostic approaches that cut across traditional psychiatric categories. Wellcome Career Development Award (£1.5 million) Wellcome Mental Health Award (£4.3 million, jointly awarded with Prof. Sarah Garfinkel) Sunday Times Book of the Year (2023) for 'The Balanced Brain: The Science of Mental Health' Financial Times Book of the Year (2023) for 'The Balanced Brain: The Science of Mental Health' Nord actively mentors PhD students and postdoctoral researchers, with her trainees receiving prestigious awards including the British Association of Psychopharmacology (BAP) Poster Prize, BAP Hannah Steinberg Bursary, and Alwyn Lishman Prize. Her lab is currently funded by MRC intramural funding, a Wellcome Career Development Award, and a Wellcome Mental Health Award, supporting innovative research at the intersection of neuroscience and mental health treatment. The Mental Health Neuroscience Lab operates within the MRC Cognition and Brain Sciences Unit, collaborating extensively with researchers across Cambridge and internationally. The lab maintains strong connections with clinical services and patient groups, ensuring research remains grounded in real-world mental health challenges. Current work focuses on transcranial ultrasound stimulation, gut-brain axis interventions, and computational modeling of mental health mechanisms.
Jethro Johnson is an Innovation Track Principal Investigator at the Kennedy Institute of Rheumatology and Deputy Director of the Oxford Centre for Microbiome Studies (OCMS) at the University of Oxford. His work integrates computational genomics and microbiome research to explore host-microbiome interactions in health and disease. PhD in Nutritional Ecology (University of Auckland, 2012) MRC Career Development Fellowship Former postdoctoral researcher at Jackson Laboratory for Genomic Medicine Research focuses on: Mechanistic understanding of gut microbiome impacts on metabolic diseases Multi-omic data integration for host-microbiome studies Computational approaches to microbiome analysis Methodological developments in 16S rRNA gene profiling Publications emphasize microbiome-disease associations, methodological innovations, and computational genomics applications across human and mouse models. Key themes include metabolic dysfunction, immune interactions, and microbial diversity analysis. Scientific recognition includes: MRC Career Development Fellowship in Computational Genomics As OCMS Deputy Director, he contributes to advancing microbiome research infrastructure and collaborative projects while leading his own computational genomics group at the Kennedy Institute.
Christopher Buckley is the Kennedy Professor of Translational Rheumatology and Director of Clinical Research at the Kennedy Institute of Rheumatology, University of Oxford. He holds concurrent roles as Director of NIHR Infrastructure for Birmingham Health Partners. His research focuses on fibroblast biology in rheumatoid arthritis (RA), stromal cell interactions, and translational medicine approaches to stratified therapy. He leads the Arthritis Therapy Acceleration Programme (A-TAP), advancing precision medicine strategies for immune-mediated inflammatory diseases. Educations: BSc Biochemistry, University of Oxford (1985) MBBS Medicine, Royal Free Hospital, London (1990) DPhil in Molecular Medicine (Wellcome Trust Fellowship) under Prof. John Bell (Oxford) Research Interests: Pathogenic fibroblast subpopulations in RA and systemic sclerosis Tissue-resident memory T cells in chronic inflammation Spatial transcriptomics of synovial and tendon tissues Pro-resolving fibroblast networks during inflammation resolution Development of biomarkers for disease flare/remission Awards & Leadership: MRC Senior Clinical Fellowship (2001) Arthritis Research UK Professorship (2002) Director, Birmingham NIHR Clinical Research Facility (2012-2017) Key Projects: Leading A-TAP's stratified pathology approach for drug development Investigating Wnt signaling in stromal inflammation Developing cellular atlases of joints using spatial transcriptomics
Dr. Thomas A. Hughes is an Associate Professor of Cancer Biology at the University of Leeds and Professor of Biosciences at York St John University. As a Group Leader at the Leeds Institute of Medical Research, he focuses on gene regulation, tumour microenvironment, and nanomedicine approaches to improve cancer outcomes. Specializes in breast cancer, colorectal cancer, and rare diseases Develops therapeutic strategies using microRNAs and biomarkers Collaborates with clinicians, engineers, and chemists for translational research His research integrates molecular pathology with clinical data through partnerships with Leeds NHS Trusts, aiming to identify novel biomarkers and targets for therapy. Recent work emphasizes cholesterol metabolism, oxysterol signaling, and nanomedicine-based drug delivery systems. Key contributions include: Over 80 peer-reviewed publications in cancer biology and molecular therapeutics Leadership in MSc programs in Molecular Medicine and Cancer Biology and Therapy Extensive experience in grant review, editorial work, and doctoral supervision Scientific awards include Fellowship of the Higher Education Academy. His lab has mentored 26 doctoral students and numerous alumni in academia, clinical practice, and industry.
Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.
Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.
Dame Fiona Powrie is a Professor of Musculoskeletal Sciences at the University of Oxford and Director of the Kennedy Institute of Rheumatology . She leads the Mucosal Immunology Research Group and serves as Director of the Oxford Centre for Microbiome Studies (OCMS) and Cluster Lead in the MRC National Mouse Genetics Network Microbiome Cluster . Roles: Director of Kennedy Institute, Professor, Research Group Leader Relevant Affiliations: Wellcome Trust Governor (2018–present), Deputy Chair (2022), Royal Society Fellow (2011) Research Interests : Fiona specializes in the interplay between the intestinal microbiota and the host immune system, focusing on how dysregulation leads to inflammatory bowel disease (IBD) . Her work has elucidated the role of regulatory T cells in maintaining gut homeostasis and identified the IL-23 pathway as critical in chronic intestinal inflammation. Current efforts aim to translate these findings into clinical therapies for IBD patients. Scientific Awards and Fellowships : Ita Askonas Award (European Federation of Immunological Societies) Louis-Jeantet Prize for Medicine (2012) Honorary Lifetime Membership (British Society of Immunology, 2021) Fellow of the Royal Society (2011), EMBO (2013), Academy of Medical Sciences (2014) International Fellow of the National Academy of Sciences (2020) Advising and Leadership : Fiona leads the Mucosal Immunology group at the Kennedy Institute, mentors researchers, and contributes to national and international scientific governance. She has been instrumental in advancing microbiome and immunology research through leadership roles at the Oxford Centre for Microbiome Studies and the MRC National Mouse Genetics Network . Labs and Teams : Fiona's research group at the Kennedy Institute of Rheumatology investigates mucosal immunity and microbiome interactions, combining experimental and clinical approaches to address inflammatory diseases.
Colin Cooper is a Professor of Cancer Genetics at the Norwich Medical School, University of East Anglia. He is also a member of the Metabolic Health and Cancer Studies research groups. His work focuses on genomic evolution, tumor microbiome dynamics, and biomarker development for prostate cancer and musculoskeletal health. Cooper’s recent research explores the interplay between cancer genetics and microbial communities, emphasizing their role in prognosis and treatment outcomes. He investigates clonal evolution in tumors, mutational signatures, and non-invasive diagnostic tools like urinary extracellular vesicles. His collaborations span genomics, microbiology, and clinical applications. 2025: Causes of evolutionary divergence in prostate cancer (Genomics, Precision Medicine) 2024: Applications of urinary extracellular vesicles... (Biomarker Development, Liquid Biopsy) 2023: Caution regarding pan-cancer microbial structure (Methodological Considerations, Microbiome Analysis) In 2022, Cooper received the European Urology Oncology SoMe Award for his contributions. His work is frequently cited and has been featured in media outlets globally, highlighting his impact on cancer and aging research.
Julia Camps is a postdoctoral research associate at the University of Oxford, Department of Computer Science. Her work bridges Computational Biology and Health Informatics, focusing on cardiac digital twin development for precision medicine applications. She specializes in combining data-driven and mechanistic approaches for in silico clinical trials, particularly through Purkinje network modeling and ECG-based calibration. Education: Informatics Engineer (2014) and Master's in Artificial Intelligence (2015-2017) from Universitat Politècnica de Catalunya PhD in Computer Science (2017-2021) at Oxford, completed within the Computational Cardiovascular Science research group under Prof Blanca Rodriguez Current role: postdoc in Prof Rodriguez's group since 2021, focusing on post-myocardial infarction disease progression Software development: open-source cardiac digital twin tools available on GitHub Her research interests center on creating patient-specific cardiac digital twins using multimodal clinical data. This work enables virtual therapy evaluation and in silico clinical trials through: Integration of statistical inference and machine learning techniques Development of Purkinje network models from clinical ECG data Electrophysiological and repolarization sequence modeling Gait detection algorithms for Parkinson's disease applications Recent publications (2024-2025) demonstrate trends in: GPU-accelerated cardiac electrophysiology simulations (MonoAlg3D) Topology-informed ECG electrode localization Sex-specific electromechanical cardiac modeling Multi-modal characterisation of diabetic cardiac deterioration Pro-arrhythmic risk assessment for stem cell therapies
Mahima Swamy is a Principal Investigator and Wellcome Trust Sir Henry Dale Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee. Her research focuses on understanding immune interactions at the intestinal epithelium, particularly the role of intraepithelial lymphocytes (IEL) in maintaining gut homeostasis and resisting infections. She leads a lab investigating IEL biology, including their regulation by PIM kinases and LRRK2 in inflammatory bowel diseases (IBD) and Crohn’s disease. Dr. Swamy earned her BSc in Biological Sciences from BITS Pilani and completed her PhD at the Max-Planck Institute in Freiburg, Germany. She held postdoctoral fellowships at CRUK London Research Institute and the University of Dundee before establishing her independent group in 2016. Her work combines proteomics, mouse models, and in vitro co-cultures to explore IEL signaling pathways and their dysregulation in diseases. Key research interests include: IEL-mediated protection against pathogens, metabolic adaptations of IEL to the gut environment, and the role of LRRK2 in intestinal immune function. Her lab collaborates with the Alessi lab to study LRRK2 inhibitors for IBD therapy. Education: BSc (BITS Pilani) → PhD (MPIIB, Germany) → Postdocs (CRUK, Dundee) Lab Members: Includes PhD students (Rebecca Pemberton, Srishti, Neema Skariah) and postdocs (Amanpreet Chawla, Purbasha Bhattacharya) Collaborations: Tayside Immunology Group, Society for Mucosal Immunology Scientific achievements include discoveries of PIM kinases in IEL function and LRRK2’s role in gut inflammation. Her group has pioneered tools like phospho-proteomic analyses and epithelial organoid:IEL co-cultures.
Yan Liu is a Senior Lecturer in Glycosciences at Imperial College's Department of Metabolism, Digestion and Reproduction (Faculty of Medicine). She leads the Wellcome Trust-funded Carbohydrate Microarray Facility and co-leads the GlycoTWINNG Network. Her research focuses on glycan-mediated interactions in host-microbiota interfaces, with applications in infectious diseases and reproductive health. She holds a B.Sc. from Peking University and a Ph.D. from the University of Bristol, followed by postdoctoral work at Imperial College under Professor Ten Feizi FRS. Her academic journey includes roles as a Microarray Project Leader and co-investigator in the March of Dimes European Preterm Birth Research Centre. She is PI of a £1.34M Wellcome Trust grant maintaining Imperial's Carbohydrate Microarray Facility, advancing glycan array technologies. Research interests span microbiology, immunology, and biomolecular chemistry, with a focus on glycobiology. Key contributions include defining glycan interactions in pathogen-host systems (e.g., Candida albicans, adenoviruses), developing glycan probes, and analyzing vaginal microbiota impacts on preterm birth. Grants and collaborations include EPSRC Translational funding and the UK 'FluTrialMAP' consortium. Labs affiliations include the Glycosciences Laboratory and Imperial's Institute of Infection.
Prof Jean Van Den Elsen is a Professor of Biochemistry at the University of Bath , affiliated with the Department of Life Sciences and several research centers including the Centre for Sustainable Chemical Technologies (CSCT) , Centre for Therapeutic Innovation , and Milner Centre for Evolution . They are actively accepting doctoral students and leading multidisciplinary projects at the intersection of structural biology and immunology. Education: Not explicitly mentioned Appointments: University of Bath (current), with collaborations across Chemistry, Biology & Biochemistry departments Research Focus: The laboratory investigates protein structural biology in two major areas: Complement System Interactions: Studying how pathogenic microbes like Staphylococcus aureus evade host immunity through complement system manipulation , with structural analysis of proteins such as C3d and C5 complexes. This work directly informs vaccine design and autoimmune disease treatment . Glycation Mechanisms: Developing diagnostic tools for detecting non-enzymatic sugar modifications linked to diabetes , Alzheimer's , and aging, with commercial partnerships like Abcam . Article Trends: Recent publications demonstrate: Structural analysis of complement evasion proteins (2022-2025) Engineering knob domains as miniature antibodies (2023) Evolutionary studies on cooperative behavior (2021-2025) Advancements in peptide synthesis platforms (2022-2023) Applications of AI protein folding (2020) Scientific Contributions: ORCID: 0000-0002-0367-1956 BBSRC Funding recipient (2023) 100+ citations across 76 research outputs Student Mentorship: Directly supervising 4 current PhD students and 1 postdoc, with a track record of mentoring 11 previous students including Daphne Jackson Fellows and MSCA researchers. Collaborations: Maintains active partnerships with Dr. Tony James (Chemistry), Dr. Rob Williams (Biochemistry), and industry partners UCB Celltech and Porton Biopharma Ltd. Their work contributes to UN Sustainable Development Goals 3 (Good Health), 12 (Responsible Consumption), and 13 (Climate Action).
